Drug Drug Interaction not checked
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The intervention phase consists of 3 periods: in period 1, the pharmacokinetics (PK) of all substrates will be evaluated in the absence of C21, in period 2, a potential inhibitory effect of C21 on the substrates be evaluated, and in period 3, the net effect of potential C21-mediated induction and inhibition on the substrates will be evaluated”In the company’s words, NCT05830799 on ClinicalTrials.gov
- Tested for
- Drug Interaction
- Main trialPhase 1
- “This is a single-centre, open-label, fixed-sequence trial to evaluate the impact of C21 on the exposure of CYP1A2, CYP2C9, CYP3A4 and P-gp substrates in healthy volunteers.”In the company’s words, NCT05830799 on ClinicalTrials.gov
- Other names
- Caffeine · Koffein Meda · Tolbutamide · Tolbutamide CF · Midazolam · Midazolam APL · Nintedanib · Ofev
Other drugs for Drug Interaction
- CagriSemaNovo Nordisk · Filed (US)
- HRS-7535Hengrui · Kailera · Filed (China)
- RibupatideHengrui · Kailera · Filed (China)
- RetatrutideEli Lilly · Phase 3
- IN-B00009HK inno.N · Phase 3
- UBT251United Laboratories · Novo Nordisk · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 11 May 2023 | A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026